Angle Share Discussion Threads

[bones698] 25/7/2024 08:47

I think there's a growing realisation that the reveine miss is more than likely and that there are very few now saying otherwise says it all. What impact it has on the share price remains to be seen but last time it wasnt very pretty at all. Wethwr they can announce something positive to lift the share price before then is very possible but with them saying only 1 or 2 deals likely before eoy it's not looking great atm

I think the last raise was at a very good price in the is market but what s different is it looks like the majority of that money came for the usa so that lessened the damage. Kudos for having that option and seeing the state of uk equity money it's a good job otherwise this would have been in single digits.

Wether that continues to be an option one has to hope so or things could get ugly if they have to go to UK equity for money.

The business made excellent progress on. Alot of fronts in 2023 and 24 yet the money is slow to grow and deals taking years to get signed.

It still comes back to the AZ 6 months trial and will that move onto a bigger deal or not. That could be a huge turning point. If it does that then wil add confidence to other such deals sling the same. If it doesn't then it's a concern.

Still wisting for Septembers results for me before I decide

[ohwhatfun] 25/7/2024 08:43

Adding to that

Before the last raise in July 2022 at 80p they had £20m cash before the raise which took it up to £40m.


The cash plus the recent raise doesn’t cover what they had before the previous raise.

Clearly they held off for deals and better market conditions, then avoided as best they could heavier discounts to get more cash.

It all points to funds needed, and logically before the year end to avoid a desperation scenario in 2025.

I wouldn’t encourage a holder to sell in light of that, as deal news/angle share spikes are known here.

But it looks like it’s coin flip gambling.

No way is revenue going to be hit without a major surprise. What is sure to hit is revenue miss news, likely interims time.

That uncertainty is why many are unwilling to invest currently.

If they had said confident 5 possibly 6 of 11 then you had a case, but still revenue unlikely to be this year.

They have said HOPE, 1 possibly 2.

So for holders it’s a case of long term (which looks good) or play the spike news lottery v revenue miss and fund raise.

For pending investors it’s sit on hands, waiting to see actual results and numbers, before doing anything, not giving a damn about retail driven spikes.

[bobbie121] 24/7/2024 23:56

FFS it’s not my life savings,I think I’ll wait.

[muffster] 24/7/2024 23:26

You don't have a Job. Clown

[havinthelasttoast] 24/7/2024 19:58

My job here is nearly done. Final push now to 12p.

Placing anyone ?

[atmysignal] 24/7/2024 15:53

Adw198 chatting to himself with his multiple handles. Hilarious

[havinthelasttoast] 24/7/2024 15:43

Cash getting low again folks?

Placing ?

[ohwhatfun] 24/7/2024 15:39

Investor logic, revenue missed, market reaction.

Quite clearly a few agree, revenue highly likely to be missed, news forced and with such re revenue factored in, it forms part of the forecast, 12 months of cash.

I was/am a pending investor, waiting for £20m in a raise around mid year, a raise forecast to happen, but trashed by holders.

Cash runway, went from Q4 to Q1 to into Q2 2025, and would have included the forecast cash.

Burn rate about £1.3m per month.

Cash Dec 23 £16.2m. All things being equal and as they were, cash June 23 about £8m

£8m would take the cash runway to Q4 as stated, the full revenue into Q1/Q2.


Raise of 6 months worth, revenue not hit should mean another raise before year end.

It all depends on forecast savings and the monthly cash burn.

So holders sit waiting for the hope of that one customer mentioned pre year end and an share price spike.

Hovering investors think (because it always happens) that the market will give AGL a kicking on the miss.


So news spike, revenue miss, which order. Either way if it went higher, followed by revenue miss, it will probably be this price or lower.
Then the dark clouds of a fund raise build, typically a spike to enable forward selling/shorting.

So the sit and wait crew see factors where they think the coin flip will
land their way, spikes prior are simply unknown unpredictable events.

So some go with what they can see, rather than rabbits foot luck.

They hope to do one deal this year, not confident on the deal, hope.

You can forget possibly 2, no hype type CEOs making likely unachievable forecasts, use hope and possibly in their pump.

It was all about avoiding a bigger discounted raise, gambling on deals.

Gamble made, we’ll see what happens in the coming months.

[millwallfan] 23/7/2024 17:58

And do we then charge ‘per test’ ?????

[fhmktg] 23/7/2024 11:36

Great find soletrader....watch for an increase in the number of Parsortix machines sold in any updates from AN.
290 at last count if my memory is ok.
Particularly in UK, US, Switzerland, Japan and Korea where major oncology centres are sited, that will show how many internal pre-trial programs are underway.

[ohwhatfun] 23/7/2024 09:10

Correction

It says 1 customer, possibly 2.

In deals minor changes can take many months to sign off.

The AZ deal is covered, it took a number of years.l, including a change that caused delays.

11 talking to, 6 of which are household names.

Only 1 that they think may do a deal this year.

Unless that deal is for multi millions (highly unlikely), then they are going to miss by a mile.
So at that scale it wouldn’t be revenue falling into this year anyway, unless it’s an up front payment.

Those details surely support the case of revenue missed by a mile this year.

It’s not the revenue miss that bothers me, it’s what the market does to the share price on the news, and that will be the news pre a pending fund raise as they didn’t raise enough in June.

Now just a 10 week wait for the interims, to see some numbers.

[ohwhatfun] 23/7/2024 08:53

As for cash burn YE 22 v YE 23 it was about £1.3m per month.

Savings Canada, apparent expansion here. Exactly what that equates to of cash left in the bank will be shown in the interims, due in 10 weeks.

If they haven’t announced deals covering the forecast revenue by then, they are not going to hit it and will need to update the market. Perhaps earlier if it’s still hope in September.


In theory £8m in the bank at the time of the raise.

Raises prior done well before this one with more cash in the bank.

The interim June 23 cash level will also identify how much truth there was in the cash runway forecasts.

Hence when you put it altogether, the half glass empty crew hardened through decades of AIM lies and false promises, are quite rightly highly suspicious about apparent inflated claims.


Taking it all into account, it points towards a material revenue miss is likely, with the market hitting the share price hard.

Yes it can spike on whatever news. Certainly a deal for multi millions this year would settle nerves.

[ohwhatfun] 23/7/2024 08:33

Just read the AGM notes Timbo thanks, and replies.

Fund raise.

No some were not saying trouble fund raising, they said trouble raising the typical required amount £20m. Previous raises have been £20m with more cash in the bank at the time of the raise.

Had they raised £20m, as per posts, various new private investors would have bought, others would add. Instead you have a number of investors doubtful of revenue claims, knowing that event triggers negative news, and the miss shortens the time to the next raise.

Why it’s difficult to raise currently at prices and amounts is in the notes.
Some mention Avacta 50p raise 75p now, it was over £1 shortly before the raise, with posters trashing others who suggested a big discounted raise was coming.

Revenue this year

HOPE to get 2 more customers this year, what over £2m each against examples of £150k. Not confident or very confident, HOPE.

Oversubscribed raise, show me news of raises where they are not oversubscribed over the years. It’s been explained a number of times, fund raises are supposed to be closed circles but are far from it. In the subscribed list for AGL would have been demand to close short positions opened in knowledge of the raise.


Just about every raise sees the share price fall below the raise price, yet AGL seem oblivious to this, suggesting incompetence.

The loss of bread and butter small company revenue in this sector is evident in other companies, 75%+ revenue drops in some cases, explained as funding drying up. That’s not AGL that’s the sector.

AGLs fix was to proactively start chasing big Pharma.


All the confidence and loud claims now seems to be based on 2 with HOPE.

Hope based on hard-nosed sale tactics. Yeah the deal is you pay for everything, we keep the IP you create and paid for.
I fail to see the buyer carrot on a stick there, minnows trying to bully majors.

The hope of 2 more customers, needs to be done swiftly to count for revenue this year. It sounds like revenue is going to be missed by some way.

That’s not a good advert for new investors to buy now. Some don’t like coin flip investment timing

[havinthelasttoast] 22/7/2024 10:58

Heard Mrs newland is not happy with her Porsche and wants a lambo urus now. AN has started discussing placings to facilitate her. Expect a placing soon.

[adw198] 22/7/2024 09:13

Bones698 is correct imo. AIM is littered with companies offering the next big thing and jam tomorrow. RENE and DEST are worth a sobering look. The reality is revenues are tiny and whilst these initial deals might lead to the next stage, they might not. And even if they do it won’t be next month, it might be next year. In the meantime there are bills to pay. Unfortunately the credibility of management will be shot to bits with a massive revenue miss. If I’m wrong on that front I’ll own it.

[5oletrader] 21/7/2024 17:51

I missed this - but a huge positive for ANGLE?• Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Grouphttps://www.annalsofoncology.org/article/S0923-7534(24)00111-X/fulltext#tbl3-Some notes I picked up on (simple enough to understand if your attention span allows):• In this UPDATED REPORT, the consensus within the group has led to an expansion of the RECOMMENDATIONS to encompass patients with ADVANCED BREAST CANCER and rare tumours such as gastrointestinal stromal tumours, sarcoma, thyroid cancer, and cancer of unknown primary.-Considering the EVOLVING FIELD of drug development and genomic data, the European Society for Medical Oncology (ESMO) Precision Medicine Working Group (PMWG) sought to update recommendations for the USE OF NEXT-GENERATION SEQUENCING (NGS) for patients with metastatic cancers published in 2020.-Precision Medicine Working Group (PMWG) CONCENTRATED ITS EFFORTS on genomic alterations classified as ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) LEVEL I, since they are the KEY DETERMINANTS for recommending the use of NGS FOR ROUTINE PRACTICE within specific cancer types. IN ADDITION, it was UNANIMOUSLY AGREED to report ESCAT LEVEL II genomic alterations to FACILITATE PATIENT ENROLMENT IN CLINICAL TRIALS and PROMOTE DRUG DEVELOPMENT.https://www.esmo.org/content/download/535994/10608635/1/ESMO-ESCAT-Framework.pdf-ESMO 'RECOMMENDS' that CLINICAL RESEARCH CENTRES 'CARRY OUT' multigene sequencing for patients with metastatic cancers in order to ACCELERATE CLINICAL RESEARCH. -Advanced Breast Cancer (ABC) - Summary of recommendations:• Considering that tumour NGS CAN SUBSTITUTE germline BRCA1/2 testing in most of the patients, along with the reclassification of ESR1 mutations to level IA, 'IT IS RECOMMENDED TO CARRY OUT TUMOUR (or PLASMA) SAMPLE' from a patient with hormone receptor-positive/HER2-negative ABC as 'STANDARD OF CARE'. The NGS testing should be done after resistance to endocrine therapy to optimise the likelihood of detecting ESR1 mutations. Patients with high likelihood of harbouring germline BRCA1/2 mutations should undergo clinical genetic testing even if these alterations were not detected by tumour NGS.-Important Considerations when Ordering an NGS + Technologies to detect fusion genes:• Chromosomal rearrangements can create potent oncogenic FUSION GENES, which represent IMPORTANT therapeutic TARGETS for precision oncology. Examples of gene fusions for which targeted drugs have been approved are those involving ALK, ROS1, RET, FGFR1/2/3, and NTRK1/2/3. In clinical practice, different technologies are employed for the identification of fusion genes. The advantages and limitations of these techniques are described in the following paragraphs. The MAIN POINT is also to stress the fact that CLINICIANS MUST ASSESS whether the NGS PANEL INCLUDES the DETECTION of the FUSIONS recommended in a specific disease. NGS panels for gene fusions detection are based on DNA and/or RNA sequencing. DNA sequencing has the advantage that DNA is more stable than RNA. However, DNA sequencing can only identify break points of translocations leading to gene fusions. These breaks may occur in large intronic regions, which may not be fully covered by a gene panel, or in regions comprising homopolymers/segmental duplication/repeated sequences, which can be challenging to sequence. Therefore, PRECISE KNOWLEDGE OF a THE GENOMIC ARCHITECTURE OF A GENE FUSION IS CRITICAL, not only for the panel design but also for the interpretation of test results. For example, a test that does not detect a fusion might be false negative if the break point region is not fully covered by the gene panel employed for the diagnostic test. Several LIMITATIONS OF DNA-BASED fusion gene sequencing are OVERCOME BY RNA-BASED sequencing methods. RNA-based gene panels identify the transcript of the fusion gene resulting from a translocation, and provide data on the 'expression' of the fusion transcript, the fusion partner as well as the potential functionality (e.g. out-of-frame versus in-frame fusions). In contrast to DNA-based assays, it does not provide information on break points. The sensitivity of NGS panels also depends on the technologies used for library preparation: hybrid capture based, amplicon based, or single primer extension (e.g. anchored multiplex PCR).-Conclusion:The ESMO PMWG recommends running tumour NGS in patients with advanced non-squamous NSCLC, 'BREAST', colorectal, prostate, and ovarian cancer. In addition, for rare tumours, it is RECOMMENDED to carry out tumour NGS IN PATIENTS WITH ADVANCED CCA, GIST, sarcoma, thyroid cancer, and unfavourable CUP. Finally, ESMO RECOMMENDS to CARRY OUT tumour NGS TO DETECT TUMOUR-AGNOSTIC ALTERATIONS IN PATIENTS with advanced cancers, IN COUNTRIES where tumour-agnostic TARGETED THERAPIES ARE ACCESSIBLE.-* IN * CLOSING * THINK *Recommendations - then process what AGL can offer NOW and in the FUTURE:• NOW - 'Currently' the CELLS harvested by the Parsortix system CAN BE ANALYSED USING EXISTING TECHNIQUES ALREADY ESTABLISHED for tissue biopsy and cell analysis including:• Next Generation Sequencing (NGS)• RNA sequencing (RNA-seq)• FUTURE - ANGLE IS DEVELOPING NUMEROUS assays for the molecular analysis of CTCs.These include:• Sample-to-answer solution for parallel analysis of CTCs and ctDNA• Digital PCR pan cancer assay• NGS pan cancer assay• Future - ANGLE IS DEVELOPING RESEARCH ASSAYS USING NGS. This includes a pan- cancer NGS PANEL THAT TARGETS HUNDREDS of loci across 61 genes using Illumina's NextSeq 2000.• Future - ANGLE IS DEVELOPING MOLECULAR SOLUTIONS so that the CTCs harvested by the Parsortix system CAN BE ANALYSED USING EXISTING laboratory instruments. This will ALLOW ANGLE TO BENEFIT FROM THE EXISTING INSTALLED BASE of digital PCR (dPCR) and Next Generation Sequencing (NGS) instruments and for Parsortix-based assays to be EASILY INCORPORATED INTO EXISTING WORKFLOWS and CLINICAL PRACTICE.-Significant imo - ATB

[bones698] 21/7/2024 16:01

Ht yes will. Look to see if he's having an impact, would be interesting to hear how AN and others rate his impact. Not something we will get to hear though but good point.

My point about October is the first AZ deal should be complete and move onto the next phase which AN says could be with 1-3m. If that happens it's a big sign that these small deals will grow as he expects so the easai and other AZ deal will turn into bigger deals too.

I still feel they are a bit further away than many think especially revenue wise so expect some short term pain but the future still looks positive and ple ty of irons in the fire.

Snake sorry but your just an annoying fool I won't be answering as there's no point. Bury your head all you like plenty on here have done that in years gone but and it's cost them dearly.
As for Gdr, I've more than tripled my money there thanks. Your deluded if you think comments on a bb make the slightest difference to a conpanies shateprice. Shows your a novice. Bye

[htrocka2] 20/7/2024 09:32

ref:bones 698..

"..We have seen a few deals but very small in size and with potential the first of which ends in October so we will see if they translate into bigger things or not."


I can well imagine you being frustrated after 15 years with this share only to have the share price 'stuck' at these levels...However, let's see how the 'new man' has performed over the past 14 months. Having spent his life within the industry must have built powerful connections around the world. My decision to stay in or pull out of this company may depend on his performance...I already hold a share that has performed poorly over 16 years...it's not a mistake I intend to make twice.

[kryptonsnake] 20/7/2024 09:07

bones698

There's always at least one person on every thread attempting to pull down a company, whether it be posting lies or just repeating out of date facts

You clearly have an agenda here. Why did you create an account on LSE 8 days ago?

To ramp Genedrive and deramp Angle?



sent from my iPhone

[sinzu] 19/7/2024 19:46

Some of us have a life. The human being behind Bones698, sadly, appears to be missing that.

[kryptonsnake] 19/7/2024 19:30

bones698 is now deramping on LSE under the name GordonGecko123

Just like adw he sold and now turns up every other day to repeat the same story as to why the share price is going to tank

You've got to be stupid to believe it's going to stay below 15p for much longer. We will be trading in the 20s before you know it



sent from my iPhone